Clinical implications of the p53 gene.
暂无分享,去创建一个
M. Hollstein | D. Sidransky | D Sidransky | M Hollstein | David Sidransky, M.D | Monica Hollstein, Ph.D
[1] D. Lane,et al. T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.
[2] A. Levine,et al. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.
[3] Y. Nakamura,et al. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. , 1989, JAMA.
[4] M. Barbosa,et al. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. , 1989, Oncogene.
[5] A. Levine,et al. Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.
[6] Arnold J. Levine,et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.
[7] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[8] B. Vogelstein,et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.
[9] B. Vogelstein,et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.
[10] P. Howley,et al. Role of the human papillomaviruses in human cancer. , 1991, Cancer research.
[11] P. Green,et al. Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.
[12] J. Simon,et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[13] B. Vogelstein,et al. Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.
[14] M. Kastan,et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[15] G. Wahl,et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.
[16] J. Minna,et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. , 1992, Cancer research.
[17] D. Wynford‐Thomas. P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.
[18] R. Knapp,et al. Unifocal origin of advanced human epithelial ovarian cancers. , 1992, Cancer research.
[19] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[20] Bert Vogelstein,et al. p53 function and dysfunction , 1992, Cell.
[21] J. Marks,et al. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[22] T. Visakorpi,et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.
[23] Thea D. Tlsty,et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.
[24] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[25] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[26] W. Hong,et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. , 1993, Cancer research.
[27] R. Hruban,et al. The incidence of p53 mutations increases with progression of head and neck cancer. , 1993, Cancer research.
[28] D. Brachman,et al. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. , 1993, Cancer research.
[29] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[30] Kathleen R. Cho,et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[31] J. Minna,et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. , 1993, Journal of the National Cancer Institute.
[32] P. Meltzer,et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. , 1993, Cancer research.
[33] P. Hainaut,et al. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. , 1993, Cancer research.
[34] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[35] M. Scheffner,et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.
[36] T. Mitsudomi,et al. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.
[37] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[38] P. Laurent-Puig,et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. , 1993, Cancer research.
[39] J. Berzofsky,et al. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. , 1994, Cancer research.
[40] M. Asada,et al. Clonal expansion of p53 mutant cells in leukemia progression in vitro. , 1994, Leukemia.
[41] J. Roth,et al. Posttranslational regulation of p53 tumor suppressor protein function. , 1994, Critical reviews in oncogenesis.
[42] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[43] R. Hruban,et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.
[44] C. Prives. How loops, β sheets, and α helices help us to understand p53 , 1994, Cell.
[45] B. Vogelstein,et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms , 1994, The Journal of pathology.
[46] D. Malkin,et al. Germline p53 mutations and heritable cancer. , 1994, Annual review of genetics.
[47] Erwin G. Van Meir,et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.
[48] D. Fisher. Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.
[49] D. Givol,et al. Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.
[50] B. Vogelstein,et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[51] Stephen J. Elledge,et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest , 1994, Cell.
[52] P. O'Connor,et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.
[53] S C Chen,et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.
[54] K. Dameron,et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.
[55] M. Espié,et al. p53 mutations and overexpression in locally advanced breast cancers. , 1994, British Journal of Cancer.
[56] R. Hruban,et al. Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. , 1994, The New England journal of medicine.
[57] C. Cordon-Cardo,et al. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] S. Elledge,et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[59] G. Hannon,et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.
[60] R Montesano,et al. Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.
[61] L. Hartwell,et al. Cell cycle control and cancer. , 1994, Science.
[62] E. Diamandis,et al. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers , 1994, International journal of cancer.
[63] D. Lane,et al. p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.
[64] D. Thorley-Lawson,et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.
[65] M. Evans,et al. p53 modulation of TFIIH–associated nucleotide excision repair activity , 1995, Nature Genetics.
[66] R H Hruban,et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.
[67] H. Steller. Mechanisms and genes of cellular suicide , 1995, Science.
[68] C. Prives,et al. Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus , 1995, Cell.
[69] R H Hruban,et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.
[70] P. Chappuis,et al. A simple p53 functional assay for screening cell lines, blood, and tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[71] D. Sidransky. Molecular markers in cancer diagnosis. , 1995, Journal of the National Cancer Institute. Monographs.
[72] M. Ewen,et al. The transcription factor E2F-1 is a downstream target of RB action , 1995, Molecular and cellular biology.
[73] S. Elledge,et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells , 1995, Science.
[74] A. Levine,et al. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches , 1995, Cell.
[75] M. Dean. Resolving DNA mutations , 1995, Nature Genetics.
[76] L. Norton,et al. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] G. Stark,et al. p53-dependent growth arrest of REF52 cells containing newly amplified DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[78] D. Lane,et al. The dominating effect of mutant p53 , 1995, Nature Genetics.
[79] K. Kinzler,et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. , 1995, Genes & development.
[80] T. Soussi,et al. Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.
[81] J. Bonneterre,et al. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer , 1995, The Lancet.
[82] M. Kirschner,et al. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA , 1995, Nature.
[83] C. Harris,et al. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. , 1995, Journal of the National Cancer Institute.
[84] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[85] Lawrence A. Donehower,et al. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice , 1995, Nature Genetics.
[86] N. Rainov,et al. Absence of p53 autoantibodies in sera from glioma patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.